Title
Epidemiology of meticillin-resistant Staphylococcus aureus (MRSA) in Latin America
Date Issued
01 October 2009
Access level
metadata only access
Resource Type
review article
Author(s)
Guzmán-Blanco M.
Mejía C.
Isturiz R.
Alvarez C.
Bavestrello L.
Labarca J.
Luna C.M.
Rodríguez-Noriega E.
Salles M.J.C.
Zurita J.
Abstract
Meticillin-resistant Staphylococcus aureus (MRSA) has become a serious threat to public health worldwide. Ongoing surveillance is essential to support infection control committees and clinicians in the prevention and treatment of infection. However, in Latin America, resources for monitoring the changing epidemiology of MRSA remain limited. In this article, we review the current situation of MRSA in Latin America in order to highlight the need for a more harmonised effort to improve its management. Literature in the PubMed and SciELO databases as well as the website of the Pan American Health Organization were searched for articles and information about the epidemiology of MRSA in Latin America. MRSA is already the leading cause of nosocomial infection in the Latin American region, and the number of reports of community-acquired MRSA infections is also rising. However, the extent of the problem is not fully understood, especially since data tend to come from large hospitals whereas much of the population is served by small community healthcare centres that do not have extensive facilities for performing microbiological surveillance. In conclusion, wider-reaching and co-ordinated programmes to provide regular MRSA surveillance reports are required across the Latin American region. © 2009 Elsevier B.V. and the International Society of Chemotherapy.
Start page
304
End page
308
Volume
34
Issue
4
Language
English
OCDE Knowledge area
Biología celular, Microbiología Epidemiología
Scopus EID
2-s2.0-67849100867
PubMed ID
Source
International Journal of Antimicrobial Agents
ISSN of the container
09248579
Sponsor(s)
Funding: Pfizer Inc. (New York, NY) provided support for meetings of the Latin American Working Group on Gram-Positive Resistance. Members of the Working Group received honoraria for attendance at the meetings. Pfizer Inc. had no involvement in the study design, in the collection, analysis and interpretation of the data, or in the decision to submit the article for publication. The support provided by Choice Pharma (Hitchin, UK), funded by Pfizer Inc., consisted solely of manuscript formatting and writing assistance.
Sources of information: Directorio de Producción Científica Scopus